Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women

Kiok O. Han, J. T. Choi, I. G. Moon, M. S. Jeong, C. H. Yim, H. Y. Chung, Hak Chul Jang, H. K. Yoon, I. K. Han

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Interleukin-1 receptor antagonist (IL-1ra), a natural inhibitor of interleukin-1 (IL-1), completely inhibits the stimulatory effects of IL-1 on bone resorption. Bioactivity of IL-1 increases in the estrogen-deficient state with an increased IL-1:IL-1ra ratio and decreases after estrogen replacement therapy with a decreased IL-1:IL-1ra ratio. An association was found between an 86 basepair variable number tandem-repeat (VNTR) polymorphism of the IL-1ra gene and an increased production of IL-1ra in a cultured monocyte system. The IL-1ra VNTR polymorphism, therefore, is an attractive candidate gene for osteoporosis susceptibility as well as hormone responsiveness after estrogen replacement. We examined the association of this VNTR polymorphism with bone mass, bone turnover, and the change of bone mineral density (BMD) after 1 year of hormone replacement therapy (HRT). The frequencies of the five alleles were as follows: A1, 90.8% (410 bp, four repeats); A2, 7.2% (240 bp, two repeats); A3, 1.6% (500 bp, five repeats); A4, 0.4% (326 bp, three repeats); and A5, 0% (595 bp, six repeats), in 714 healthy ethnically Korean postmenopausal women, aged 41-74 years (55.2 ± 6.3 years mean ± SD). Spine (L2-4) and femoral neck BMD were not significantly different among IL-1ra genotypes, and no significant genotypic differences were found in bone markers. There were no differences in genotypic proportions when we categorized the subjects into a high-loss group and a normal-loss group with regard to levels of bone marker. No significant genotypic differences were found in changes in lumbar and femoral neck BMD and those in bone markers before and after 1 year of HRT in 312 women. Our data suggest that these IL-1ra polymorphisms are not associated with BMD, bone turnover, or the change of BMD after 1 year of HRT in Korean women.

Original languageEnglish
Pages (from-to)612-615
Number of pages4
JournalBone
Volume31
Issue number5
DOIs
StatePublished - 1 Nov 2002

Fingerprint

Interleukin-1 Receptors
Bone Remodeling
Bone Density
Estrogens
Genotype
Interleukin-1
Minisatellite Repeats
Hormone Replacement Therapy
Bone and Bones
Estrogen Replacement Therapy
Femur Neck
Bone Resorption
varespladib methyl
Gene Frequency
Genes
Osteoporosis
Monocytes
Spine
Hormones

Keywords

  • Bone mass
  • Genetics
  • Hormone replacement therapy (HRT)
  • Interleukin-1 receptor antagonist (IL-1ra)
  • Osteoporosis
  • Polymorphism

Cite this

Han, Kiok O. ; Choi, J. T. ; Moon, I. G. ; Jeong, M. S. ; Yim, C. H. ; Chung, H. Y. ; Jang, Hak Chul ; Yoon, H. K. ; Han, I. K. / Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women. In: Bone. 2002 ; Vol. 31, No. 5. pp. 612-615.
@article{e6477235b890486a93ba3c2ce3ac0407,
title = "Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women",
abstract = "Interleukin-1 receptor antagonist (IL-1ra), a natural inhibitor of interleukin-1 (IL-1), completely inhibits the stimulatory effects of IL-1 on bone resorption. Bioactivity of IL-1 increases in the estrogen-deficient state with an increased IL-1:IL-1ra ratio and decreases after estrogen replacement therapy with a decreased IL-1:IL-1ra ratio. An association was found between an 86 basepair variable number tandem-repeat (VNTR) polymorphism of the IL-1ra gene and an increased production of IL-1ra in a cultured monocyte system. The IL-1ra VNTR polymorphism, therefore, is an attractive candidate gene for osteoporosis susceptibility as well as hormone responsiveness after estrogen replacement. We examined the association of this VNTR polymorphism with bone mass, bone turnover, and the change of bone mineral density (BMD) after 1 year of hormone replacement therapy (HRT). The frequencies of the five alleles were as follows: A1, 90.8{\%} (410 bp, four repeats); A2, 7.2{\%} (240 bp, two repeats); A3, 1.6{\%} (500 bp, five repeats); A4, 0.4{\%} (326 bp, three repeats); and A5, 0{\%} (595 bp, six repeats), in 714 healthy ethnically Korean postmenopausal women, aged 41-74 years (55.2 ± 6.3 years mean ± SD). Spine (L2-4) and femoral neck BMD were not significantly different among IL-1ra genotypes, and no significant genotypic differences were found in bone markers. There were no differences in genotypic proportions when we categorized the subjects into a high-loss group and a normal-loss group with regard to levels of bone marker. No significant genotypic differences were found in changes in lumbar and femoral neck BMD and those in bone markers before and after 1 year of HRT in 312 women. Our data suggest that these IL-1ra polymorphisms are not associated with BMD, bone turnover, or the change of BMD after 1 year of HRT in Korean women.",
keywords = "Bone mass, Genetics, Hormone replacement therapy (HRT), Interleukin-1 receptor antagonist (IL-1ra), Osteoporosis, Polymorphism",
author = "Han, {Kiok O.} and Choi, {J. T.} and Moon, {I. G.} and Jeong, {M. S.} and Yim, {C. H.} and Chung, {H. Y.} and Jang, {Hak Chul} and Yoon, {H. K.} and Han, {I. K.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1016/S8756-3282(02)00873-6",
language = "English",
volume = "31",
pages = "612--615",
journal = "Bone",
issn = "8756-3282",
publisher = "Elsevier Inc.",
number = "5",

}

Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women. / Han, Kiok O.; Choi, J. T.; Moon, I. G.; Jeong, M. S.; Yim, C. H.; Chung, H. Y.; Jang, Hak Chul; Yoon, H. K.; Han, I. K.

In: Bone, Vol. 31, No. 5, 01.11.2002, p. 612-615.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Nonassociation of interleukin-1 receptor antagonist genotypes with bone mineral density, bone turnover status, and estrogen responsiveness in Korean postmenopausal women

AU - Han, Kiok O.

AU - Choi, J. T.

AU - Moon, I. G.

AU - Jeong, M. S.

AU - Yim, C. H.

AU - Chung, H. Y.

AU - Jang, Hak Chul

AU - Yoon, H. K.

AU - Han, I. K.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - Interleukin-1 receptor antagonist (IL-1ra), a natural inhibitor of interleukin-1 (IL-1), completely inhibits the stimulatory effects of IL-1 on bone resorption. Bioactivity of IL-1 increases in the estrogen-deficient state with an increased IL-1:IL-1ra ratio and decreases after estrogen replacement therapy with a decreased IL-1:IL-1ra ratio. An association was found between an 86 basepair variable number tandem-repeat (VNTR) polymorphism of the IL-1ra gene and an increased production of IL-1ra in a cultured monocyte system. The IL-1ra VNTR polymorphism, therefore, is an attractive candidate gene for osteoporosis susceptibility as well as hormone responsiveness after estrogen replacement. We examined the association of this VNTR polymorphism with bone mass, bone turnover, and the change of bone mineral density (BMD) after 1 year of hormone replacement therapy (HRT). The frequencies of the five alleles were as follows: A1, 90.8% (410 bp, four repeats); A2, 7.2% (240 bp, two repeats); A3, 1.6% (500 bp, five repeats); A4, 0.4% (326 bp, three repeats); and A5, 0% (595 bp, six repeats), in 714 healthy ethnically Korean postmenopausal women, aged 41-74 years (55.2 ± 6.3 years mean ± SD). Spine (L2-4) and femoral neck BMD were not significantly different among IL-1ra genotypes, and no significant genotypic differences were found in bone markers. There were no differences in genotypic proportions when we categorized the subjects into a high-loss group and a normal-loss group with regard to levels of bone marker. No significant genotypic differences were found in changes in lumbar and femoral neck BMD and those in bone markers before and after 1 year of HRT in 312 women. Our data suggest that these IL-1ra polymorphisms are not associated with BMD, bone turnover, or the change of BMD after 1 year of HRT in Korean women.

AB - Interleukin-1 receptor antagonist (IL-1ra), a natural inhibitor of interleukin-1 (IL-1), completely inhibits the stimulatory effects of IL-1 on bone resorption. Bioactivity of IL-1 increases in the estrogen-deficient state with an increased IL-1:IL-1ra ratio and decreases after estrogen replacement therapy with a decreased IL-1:IL-1ra ratio. An association was found between an 86 basepair variable number tandem-repeat (VNTR) polymorphism of the IL-1ra gene and an increased production of IL-1ra in a cultured monocyte system. The IL-1ra VNTR polymorphism, therefore, is an attractive candidate gene for osteoporosis susceptibility as well as hormone responsiveness after estrogen replacement. We examined the association of this VNTR polymorphism with bone mass, bone turnover, and the change of bone mineral density (BMD) after 1 year of hormone replacement therapy (HRT). The frequencies of the five alleles were as follows: A1, 90.8% (410 bp, four repeats); A2, 7.2% (240 bp, two repeats); A3, 1.6% (500 bp, five repeats); A4, 0.4% (326 bp, three repeats); and A5, 0% (595 bp, six repeats), in 714 healthy ethnically Korean postmenopausal women, aged 41-74 years (55.2 ± 6.3 years mean ± SD). Spine (L2-4) and femoral neck BMD were not significantly different among IL-1ra genotypes, and no significant genotypic differences were found in bone markers. There were no differences in genotypic proportions when we categorized the subjects into a high-loss group and a normal-loss group with regard to levels of bone marker. No significant genotypic differences were found in changes in lumbar and femoral neck BMD and those in bone markers before and after 1 year of HRT in 312 women. Our data suggest that these IL-1ra polymorphisms are not associated with BMD, bone turnover, or the change of BMD after 1 year of HRT in Korean women.

KW - Bone mass

KW - Genetics

KW - Hormone replacement therapy (HRT)

KW - Interleukin-1 receptor antagonist (IL-1ra)

KW - Osteoporosis

KW - Polymorphism

UR - http://www.scopus.com/inward/record.url?scp=1842848028&partnerID=8YFLogxK

U2 - 10.1016/S8756-3282(02)00873-6

DO - 10.1016/S8756-3282(02)00873-6

M3 - Article

C2 - 12477576

AN - SCOPUS:1842848028

VL - 31

SP - 612

EP - 615

JO - Bone

JF - Bone

SN - 8756-3282

IS - 5

ER -